Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age22-27
SponsorMiriam Elfström
About this trial
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.
Eligibility criteria
Qualifiers
Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.
Disqualifiers
Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate
Known history of immune-related disorders
Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose
Trial design
Treatments tested in this trial
- Gardasil9
Treatment groups
150,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Miriam Elfström
Lead sponsor
Region Stockholm
Sponsor institution
Karolinska University Hospital
Collaborator
Source ClinicalTrials.gov